185 related articles for article (PubMed ID: 30632715)
1. Designing Next-Generation Local Drug Delivery Vehicles for Glioblastoma Adjuvant Chemotherapy: Lessons from the Clinic.
Tabet A; Jensen MP; Parkins CC; Patil PG; Watts C; Scherman OA
Adv Healthc Mater; 2019 Feb; 8(3):e1801391. PubMed ID: 30632715
[TBL] [Abstract][Full Text] [Related]
2. Polymeric drug delivery for the treatment of glioblastoma.
Wait SD; Prabhu RS; Burri SH; Atkins TG; Asher AL
Neuro Oncol; 2015 Mar; 17 Suppl 2(Suppl 2):ii9-ii23. PubMed ID: 25746091
[TBL] [Abstract][Full Text] [Related]
3. MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers.
Gutenberg A; Bock HC; Brück W; Doerner L; Mehdorn HM; Roggendorf W; Westphal M; Felsberg J; Reifenberger G; Giese A
Br J Neurosurg; 2013 Dec; 27(6):772-8. PubMed ID: 23662801
[TBL] [Abstract][Full Text] [Related]
4. Pattern of recurrence following local chemotherapy with biodegradable carmustine (BCNU) implants in patients with glioblastoma.
Giese A; Kucinski T; Knopp U; Goldbrunner R; Hamel W; Mehdorn HM; Tonn JC; Hilt D; Westphal M
J Neurooncol; 2004 Feb; 66(3):351-60. PubMed ID: 15015668
[TBL] [Abstract][Full Text] [Related]
5. Current status of local therapy in malignant gliomas--a clinical review of three selected approaches.
Juratli TA; Schackert G; Krex D
Pharmacol Ther; 2013 Sep; 139(3):341-58. PubMed ID: 23694764
[TBL] [Abstract][Full Text] [Related]
6. Drug delivery approaches for the treatment of glioblastoma multiforme.
Fakhoury M
Artif Cells Nanomed Biotechnol; 2016 Sep; 44(6):1365-73. PubMed ID: 26046399
[TBL] [Abstract][Full Text] [Related]
7. Concurrent blood-brain barrier opening and local drug delivery using drug-carrying microbubbles and focused ultrasound for brain glioma treatment.
Ting CY; Fan CH; Liu HL; Huang CY; Hsieh HY; Yen TC; Wei KC; Yeh CK
Biomaterials; 2012 Jan; 33(2):704-12. PubMed ID: 22019122
[TBL] [Abstract][Full Text] [Related]
8. Incomplete copolymer degradation of in situ chemotherapy.
Bourdillon P; Boissenot T; Goldwirt L; Nicolas J; Apra C; Carpentier A
J Mater Sci Mater Med; 2018 Feb; 29(3):25. PubMed ID: 29455370
[TBL] [Abstract][Full Text] [Related]
9. Safety and Effectiveness of Bis-Chloroethylnitrosourea Wafer Chemotherapy in Elderly Patients with Recurrent Glioblastoma.
Klein J; Juratli TA; Radev Y; Daubner D; Soucek S; Schackert G; Krex D
Oncology; 2017; 93(1):43-50. PubMed ID: 28395288
[TBL] [Abstract][Full Text] [Related]
10. Nanocarriers for the treatment of glioblastoma multiforme: Current state-of-the-art.
Karim R; Palazzo C; Evrard B; Piel G
J Control Release; 2016 Apr; 227():23-37. PubMed ID: 26892752
[TBL] [Abstract][Full Text] [Related]
11. Targeting glioblastoma-derived pericytes improves chemotherapeutic outcome.
Guerra DAP; Paiva AE; Sena IFG; Azevedo PO; Silva WN; Mintz A; Birbrair A
Angiogenesis; 2018 Nov; 21(4):667-675. PubMed ID: 29761249
[TBL] [Abstract][Full Text] [Related]
12. Sustained Delivery of Doxorubicin via Acetalated Dextran Scaffold Prevents Glioblastoma Recurrence after Surgical Resection.
Graham-Gurysh E; Moore KM; Satterlee AB; Sheets KT; Lin FC; Bachelder EM; Miller CR; Hingtgen SD; Ainslie KM
Mol Pharm; 2018 Mar; 15(3):1309-1318. PubMed ID: 29342360
[TBL] [Abstract][Full Text] [Related]
13. Novel delivery strategies for glioblastoma.
Zhou J; Atsina KB; Himes BT; Strohbehn GW; Saltzman WM
Cancer J; 2012; 18(1):89-99. PubMed ID: 22290262
[TBL] [Abstract][Full Text] [Related]
14. [What type of adjuvant chemotherapy should be proposed for the initial treatment of glioblastoma?].
Ducray F; Honnorat J
Presse Med; 2007 Sep; 36(9 Pt 2):1249-54. PubMed ID: 17350791
[TBL] [Abstract][Full Text] [Related]
15. Rationally designed drug delivery systems for the local treatment of resected glioblastoma.
Bastiancich C; Malfanti A; Préat V; Rahman R
Adv Drug Deliv Rev; 2021 Oct; 177():113951. PubMed ID: 34461201
[TBL] [Abstract][Full Text] [Related]
16. Design of Biopolymer-Based Interstitial Therapies for the Treatment of Glioblastoma.
Pena ES; Graham-Gurysh EG; Bachelder EM; Ainslie KM
Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884965
[TBL] [Abstract][Full Text] [Related]
17. Brain targeted delivery of carmustine using solid lipid nanoparticles modified with tamoxifen and lactoferrin for antitumor proliferation.
Kuo YC; Cheng SJ
Int J Pharm; 2016 Feb; 499(1-2):10-19. PubMed ID: 26721730
[TBL] [Abstract][Full Text] [Related]
18. Outcome of patients affected by newly diagnosed glioblastoma undergoing surgery assisted by 5-aminolevulinic acid guided resection followed by BCNU wafers implantation: a 3-year follow-up.
Della Puppa A; Lombardi G; Rossetto M; Rustemi O; Berti F; Cecchin D; Gardiman MP; Rolma G; Persano L; Zagonel V; Scienza R
J Neurooncol; 2017 Jan; 131(2):331-340. PubMed ID: 27757721
[TBL] [Abstract][Full Text] [Related]
19. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma.
Westphal M; Hilt DC; Bortey E; Delavault P; Olivares R; Warnke PC; Whittle IR; Jääskeläinen J; Ram Z
Neuro Oncol; 2003 Apr; 5(2):79-88. PubMed ID: 12672279
[TBL] [Abstract][Full Text] [Related]
20. The role of Gliadel wafers in the treatment of newly diagnosed GBM: a meta-analysis.
Xing WK; Shao C; Qi ZY; Yang C; Wang Z
Drug Des Devel Ther; 2015; 9():3341-8. PubMed ID: 26170620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
